These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 21763506)

  • 1. HIV-1 replication in monocyte-derived dendritic cells is stimulated by melarsoprol, one of the main drugs against human African trypanosomiasis.
    Barat C; Pepin J; Tremblay MJ
    J Mol Biol; 2011 Jul; 410(5):1052-64. PubMed ID: 21763506
    [TBL] [Abstract][Full Text] [Related]  

  • 2. HIV-1 Gag-virus-like particles inhibit HIV-1 replication in dendritic cells and T cells through IFN-α-dependent upregulation of APOBEC3G and 3F.
    Chang MO; Suzuki T; Yamamoto N; Watanabe M; Takaku H
    J Innate Immun; 2012; 4(5-6):579-90. PubMed ID: 22739040
    [TBL] [Abstract][Full Text] [Related]  

  • 3. IFN-α induces APOBEC3G, F, and A in immature dendritic cells and limits HIV-1 spread to CD4+ T cells.
    Mohanram V; Sköld AE; Bächle SM; Pathak SK; Spetz AL
    J Immunol; 2013 Apr; 190(7):3346-53. PubMed ID: 23427247
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Melarsoprol cyclodextrin inclusion complexes as promising oral candidates for the treatment of human African trypanosomiasis.
    Rodgers J; Jones A; Gibaud S; Bradley B; McCabe C; Barrett MP; Gettinby G; Kennedy PG
    PLoS Negl Trop Dis; 2011 Sep; 5(9):e1308. PubMed ID: 21909447
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Melarsoprol Resistance in African Trypanosomiasis.
    Fairlamb AH; Horn D
    Trends Parasitol; 2018 Jun; 34(6):481-492. PubMed ID: 29705579
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An alternative form of melarsoprol in sleeping sickness.
    Kennedy PG
    Trends Parasitol; 2012 Aug; 28(8):307-10. PubMed ID: 22704910
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of melarsoprol treatment on circulating IL-10 and TNF-alpha levels in human African trypanosomiasis.
    Rhind SG; Sabiston BH; Shek PN; Buguet A; Muanga G; Stanghellini A; Dumas M; Radomski MW
    Clin Immunol Immunopathol; 1997 May; 83(2):185-9. PubMed ID: 9143380
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Arsenical resistance and difluoromethylornithine in the treatment of human African trypanosomiasis].
    Kazyumba GL; Ruppol JF; Tshefu AK; Nkanga N
    Bull Soc Pathol Exot Filiales; 1988; 81(3 Pt 2):591-4. PubMed ID: 3143492
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identification of an arsenic-sensitive block to primate lentiviral infection of human dendritic cells.
    Pion M; Stalder R; Correa R; Mangeat B; Towers GJ; Piguet V
    J Virol; 2007 Nov; 81(21):12086-90. PubMed ID: 17728230
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Arsenic modulates APOBEC3G-mediated restriction to HIV-1 infection in myeloid dendritic cells.
    Stalder R; Blanchet F; Mangeat B; Piguet V
    J Leukoc Biol; 2010 Dec; 88(6):1251-8. PubMed ID: 20807705
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Induction of heat-shock protein 70 by prostaglandin A₁ inhibits HIV-1 Vif-mediated degradation of APOBEC3G.
    Sugiyama R; Abe M; Nishitsuji H; Murakami Y; Takeuchi H; Takaku H
    Antiviral Res; 2013 Sep; 99(3):307-11. PubMed ID: 23831493
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Alternative application of melarsoprol for treatment of T. B. gambiense sleeping sickness. Preliminary results.
    Burri C; Blum J; Brun R
    Ann Soc Belg Med Trop; 1995 Mar; 75(1):65-71. PubMed ID: 7794064
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Current chemotherapy of human African trypanosomiasis.
    Docampo R; Moreno SN
    Parasitol Res; 2003 Jun; 90 Supp 1():S10-3. PubMed ID: 12811544
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Alpha interferon potently enhances the anti-human immunodeficiency virus type 1 activity of APOBEC3G in resting primary CD4 T cells.
    Chen K; Huang J; Zhang C; Huang S; Nunnari G; Wang FX; Tong X; Gao L; Nikisher K; Zhang H
    J Virol; 2006 Aug; 80(15):7645-57. PubMed ID: 16840343
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Advances in sleeping sickness therapy.
    Van Nieuwenhove S
    Ann Soc Belg Med Trop; 1992; 72 Suppl 1():39-51. PubMed ID: 1417168
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The role of Trypanosoma brucei MRPA in melarsoprol susceptibility.
    Alibu VP; Richter C; Voncken F; Marti G; Shahi S; Renggli CK; Seebeck T; Brun R; Clayton C
    Mol Biochem Parasitol; 2006 Mar; 146(1):38-44. PubMed ID: 16343658
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effectiveness of a 10-day melarsoprol schedule for the treatment of late-stage human African trypanosomiasis: confirmation from a multinational study (IMPAMEL II).
    Schmid C; Richer M; Bilenge CM; Josenando T; Chappuis F; Manthelot CR; Nangouma A; Doua F; Asumu PN; Simarro PP; Burri C
    J Infect Dis; 2005 Jun; 191(11):1922-31. PubMed ID: 15871127
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Melarsoprol].
    Simon F
    Med Trop (Mars); 1999; 59(4):331-2. PubMed ID: 10816741
    [No Abstract]   [Full Text] [Related]  

  • 19. Eflornithine is safer than melarsoprol for the treatment of second-stage Trypanosoma brucei gambiense human African trypanosomiasis.
    Chappuis F; Udayraj N; Stietenroth K; Meussen A; Bovier PA
    Clin Infect Dis; 2005 Sep; 41(5):748-51. PubMed ID: 16080099
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Therapeutic failure of melarsoprol among patients treated for late stage T.b. gambiense human African trypanosomiasis in Uganda].
    Legros D; Fournier C; Gastellu Etchegorry M; Maiso F; Szumilin E
    Bull Soc Pathol Exot; 1999 Jul; 92(3):171-2. PubMed ID: 10472443
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.